In an oxazolone-induced mouse atopic dermatitis model and IMQ-induced skin inflammation, we showed the enhanced anti-inflammatory effect of dual targeting of IL-17A and IL-36R employing a surrogate anti-mouse IL-36R mAb HB0034A and a mouse cross-reactive anti-human IL17A mAb HB0017, compared to single mAbs. This evidence concerns the gene IL1RL2 and atopic eczema.